Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives Average Recommendation of “Buy” from Brokerages

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has been assigned a consensus rating of “Buy” from the five analysts that are currently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $36.60.

Several equities research analysts have issued reports on KNSA shares. JPMorgan Chase & Co. boosted their price objective on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Evercore ISI boosted their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Finally, Wedbush reissued an “outperform” rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Monday, January 13th.

Insider Transactions at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 14,000 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $18.24, for a total value of $255,360.00. Following the completion of the sale, the chief operating officer now owns 88,975 shares of the company’s stock, valued at approximately $1,622,904. This represents a 13.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Mark Ragosa sold 8,969 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total transaction of $192,385.05. Following the transaction, the chief financial officer now owns 22,958 shares of the company’s stock, valued at approximately $492,449.10. This trade represents a 28.09 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,092 shares of company stock valued at $745,589. Company insiders own 54.57% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of KNSA. CWM LLC raised its stake in shares of Kiniksa Pharmaceuticals by 443.0% during the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $61,000 after acquiring an additional 1,998 shares in the last quarter. Essex Investment Management Co. LLC increased its stake in Kiniksa Pharmaceuticals by 0.4% during the 3rd quarter. Essex Investment Management Co. LLC now owns 200,516 shares of the company’s stock valued at $5,011,000 after purchasing an additional 717 shares in the last quarter. nVerses Capital LLC acquired a new position in Kiniksa Pharmaceuticals during the 3rd quarter valued at approximately $80,000. Hennion & Walsh Asset Management Inc. increased its stake in Kiniksa Pharmaceuticals by 7.6% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 195,852 shares of the company’s stock valued at $4,894,000 after purchasing an additional 13,886 shares in the last quarter. Finally, Semanteon Capital Management LP acquired a new position in Kiniksa Pharmaceuticals during the 3rd quarter valued at approximately $551,000. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Price Performance

Kiniksa Pharmaceuticals stock opened at $19.74 on Monday. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of -140.99 and a beta of 0.32. Kiniksa Pharmaceuticals has a 1 year low of $16.56 and a 1 year high of $28.15. The firm has a 50-day moving average of $19.82 and a two-hundred day moving average of $22.84.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.